Dr Reddys unveils generic Ciprodex in US to treat bacterial infection
New Delhi: Dr Reddys Laboratories Ltd on Tuesday announced the launch of a generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension in the American market, following approval from the US Food and Drug Administration (USFDA).
Ciprodexis used in adults and children 6 months of age or older to treat certain types of infections caused by certain germs called bacteria.
"We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bringing affordable generic medicines to market for patients. At the same time, this product demonstrates that we are actively expanding the depth of our portfolio with our first otic suspension dosage form," Marc Kikuchi, Chief Executive Officer of North America Generics, Dr Reddy's said in a release.
The Ciprodex brand had US sales of approximately USD 453 million MAT (moving annual turnover) for the most recent 12 months ending in June 2020, the drugmaker said, quoting market data. Dr Reddys Ciprofloxacin 0.3 percent and Dexamethasone 0.1 percent Otic Suspension, USP, is available as 7.5 ml fill in a 10 ml bottle, it said.
Also Read: Dr Reddys Labs PAT Down By 13 Percent To Rs 579.3 Crore, Gears Up To Launch 2 COVID Drugs Next Month
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.